Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Shunya Nakashita"'
Autor:
Junta Yamamichi, Yasunori Kawaguchi, Taiga Otsuka, Shunya Nakashita, Hideaki Mizobe, Yuichiro Eguchi, Shinya Kimura
Publikováno v:
JGH Open, Vol 4, Iss 2, Pp 145-152 (2020)
Background and Aim To better predict patient survival, we used automated tumor volume and density measurements to make an objective radiological assessment of the response of advanced hepatocellular carcinoma (HCC) to treatment with sorafenib. Method
Externí odkaz:
https://doaj.org/article/dde8ef74a62446089d0507fb70f6a645
Autor:
Taiga Otsuka, Shunya Nakashita, Kimihiko Yanagita, Keisuke Ario, Hiroaki Kawasoe, Seiji Kawazoe, Yuichiro Eguchi, Toshihiko Mizuta
Publikováno v:
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Externí odkaz:
https://doaj.org/article/7915344b4090486b897d19ee9ffc3666
Autor:
Yuichiro Eguchi, Shunya Nakashita, Hideaki Mizobe, Shinya Kimura, Junta Yamamichi, Taiga Otsuka, Yasunori Kawaguchi
Publikováno v:
JGH Open, Vol 4, Iss 2, Pp 145-152 (2020)
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
Background and Aim To better predict patient survival, we used automated tumor volume and density measurements to make an objective radiological assessment of the response of advanced hepatocellular carcinoma (HCC) to treatment with sorafenib. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::018048c519345e5ddced99acf9c9f379
https://doi.org/10.1002/jgh3.12230
https://doi.org/10.1002/jgh3.12230
Autor:
Eiji Sadashima, Koichi Shinchi, Yasunori Kawaguchi, Kaoru Shibayama, Futa Koga, Toshifumi Kosugi, Kentaro Kurobe, Shunya Nakashita, Norio Ureshino, Noriko Oza, Taiga Otsuka
Publikováno v:
Asian Journal of Human Services. 19:42-54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faa24b2ec51dddc4a2c91e8823914429
https://doi.org/10.14391/ajhs.19.42
https://doi.org/10.14391/ajhs.19.42
Autor:
Hirokazu Takahashi, Yujiro Ueda, Futa Koga, Azusa Komori, Shiho Arima, Norio Ureshino, Toshihiko Mizuta, Mototsugu Shimokawa, Akitaka Makiyama, Kenta Nio, Takuya Honda, Masaru Fukahori, Noriko Oza, Kenichiro Murayama, Satoshi Otsu, Yasunori Kawaguchi, Hiroki Taguchi, Shunya Nakashita, Tsuyoshi Shirakawa, Junichi Nakazawa, Taiga Otsuka, Yasushi Ide, Kenji Mitsugi, Taro Shibuki
Publikováno v:
Journal of geriatric oncology. 13(1)
This study aimed to examine the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) in older patients with metastatic pancreatic cancer (MPC), especially those ≥75 years old.This study retrospectively enrolled 153 patients with MPC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e033340aeead1ef54a5c285033f7a279
https://pubmed.ncbi.nlm.nih.gov/34215525
https://pubmed.ncbi.nlm.nih.gov/34215525
Autor:
Taro Shibuki, Taiga Otsuka, Hiroshi Isoda, Norimasa Araki, Yoshihito Kubotsu, Yasunori Kawaguchi, Shunya Nakashita, Wataru Yoshioka, Seiji Kawazoe, Hiroaki Kawasoe, Yasushi Ide, Toshihiko Mizuta, Saga Study Group of Liver Diseases (SASLD)
Publikováno v:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
BACKGROUND It is important to avoid relapse in autoimmune hepatitis (AIH) because repeated multiple relapses have been associated with a worse prognosis. However, risk factors for relapse before initiation of treatment are not fully understood. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e222f52f111df400218960ad4b4da312
https://doi.org/10.12659/msm.902576
https://doi.org/10.12659/msm.902576
Autor:
Wataru Yoshioka, Osamu Ikeda, Yasunori Kawaguchi, Yunosuke Nishihara, Hiroki Koga, Michiaki Akashi, Seiji Sato, Shinichi Aishima, Hiroaki Nakamura, Masatsugu Hiraki, Hitoshi Aibe, Shinya Azama, Atsushi Miyoshi, Toshiya Tanaka, Hiroshi Kubo, Shunya Nakashita, Kenji Kitahara, Daisuke Mori
Publikováno v:
International Journal of Surgery Case Reports
Highlights • Undifferentiated carcinoma of the liver is extremely rare disease. • We experienced a long-term survivor of undifferentiated carcinoma of the liver successfully treated with radical hepatectomy. • The tumor showed a huge hypovascul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b5810dd01e8cf2ab775441e8458ce3
https://pubmed.ncbi.nlm.nih.gov/30142599
https://pubmed.ncbi.nlm.nih.gov/30142599
Autor:
Yuichiro Eguchi, Hiroaki Kawasoe, Seiji Kawazoe, Keisuke Ario, Shunya Nakashita, Taiga Otsuka, Kimihiko Yanagita, Toshihiko Mizuta
Publikováno v:
Diseases
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Volume 3
Issue 2
Pages 68-77
Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Volume 3
Issue 2
Pages 68-77
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62b9f92161d11d98a5d646411a596ca
http://europepmc.org/articles/PMC5548234
http://europepmc.org/articles/PMC5548234
Autor:
Noriko Oza, Toshihiko Mizuta, Yuichiro Eguchi, Naofumi Ono, Shunya Nakashita, Hirokazu Takahashi, Yasunori Kawaguchi, Takahisa Eguchi, Eriko Ishibashi, Takuya Kuwashiro, Kazuma Fujimoto, Iwata Ozaki, Shinji Iwane, Keizo Anzai, Yoichiro Kitajima
Publikováno v:
Hepatology Research. 44:812-817
Aim To investigate the efficacy of ezetimibe and lifestyle intervention for treating patients with non-alcoholic fatty liver disease (NAFLD) and residual dyslipidemia via a combination of ezetimibe and lifestyle intervention. Methods Patients with NA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51f3b7b88cbbd690388946c2ed7ec862
https://doi.org/10.1111/hepr.12176
https://doi.org/10.1111/hepr.12176
Autor:
Toshihiko Mizuta, Yuichiro Eguchi, Keizo Anzai, Hirokazu Takahashi, Seiji Kawazoe, Kazuma Fujimoto, Noriko Oza, Iwata Ozaki, Taiga Otsuka, Yasunori Kawaguchi, Shunya Nakashita, Shinji Iwane, Satoshi Oeda, Takuya Kuwashiro
Publikováno v:
Internal medicine (Tokyo, Japan). 54(24)
Objective Insulin resistance (IR) modifies the anti-viral effects of interferon (IFN) therapy in patients with chronic hepatitis C (CHC). This prospective study evaluated whether lifestyle interventions improve the anti-viral response to treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a76ee4e81634095e0f0e1abddc5deb2
https://pubmed.ncbi.nlm.nih.gov/26666596
https://pubmed.ncbi.nlm.nih.gov/26666596